Our top pick for
Building a portfolio
vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 26 staff and has a trailing 12-month revenue of around USD$22,000.
|Latest market close||USD$2.15|
|52-week range||USD$1.47 - USD$4.19|
|50-day moving average||USD$1.7749|
|200-day moving average||USD$2.1898|
|Wall St. target price||USD$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.563|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||N/A|
|1 month (2020-12-23)||3.37%|
|3 months (2020-10-19)||N/A|
|6 months (2020-07-19)||N/A|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||N/A|
|5 years (2016-01-19)||N/A|
|Gross profit TTM||USD$-12,355,000|
|Return on assets TTM||-155.17%|
|Return on equity TTM||0%|
|Market capitalisation||USD$145.7 million|
TTM: trailing 12 months
There are currently 2.1 million vTv Therapeutics shares held short by investors – that's known as vTv Therapeutics's "short interest". This figure is 8% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting vTv Therapeutics shares can be evaluated.
vTv Therapeutics's "short interest ratio" (SIR) is the quantity of vTv Therapeutics shares currently shorted divided by the average quantity of vTv Therapeutics shares traded daily (recently around 902524.13793103). vTv Therapeutics's SIR currently stands at 2.32. In other words for every 100,000 vTv Therapeutics shares traded daily on the market, roughly 2320 shares are currently held short.
However vTv Therapeutics's short interest can also be evaluated against the total number of vTv Therapeutics shares, or, against the total number of tradable vTv Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case vTv Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 vTv Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.1266% of the tradable shares (for every 100,000 tradable vTv Therapeutics shares, roughly 127 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against vTv Therapeutics.
Find out more about how you can short vTv Therapeutics stock.
We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $1.47 up to $4.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -2.115. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.